Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. ExpreS2ion Biotech Holding AB's selling, general, & admin. expense for the
three
months ended in Mar. 2026 was kr0.00 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.00 Mil.
ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
ExpreS2ion Biotech Holding AB Selling, General, & Admin. Expense Related Terms
ExpreS2ion Biotech Holding AB Selling, General, & Admin. Expense Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ExpreS2ion Biotech Holding AB Selling, General, & Admin. Expense Chart
OSTO:EXPRS2 vs VRTX, REGN, RVMD: Selling, General, & Admin. Expense Comparison
For the Biotechnology subindustry, ExpreS2ion Biotech Holding AB's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ExpreS2ion Biotech Holding AB Selling, General, & Admin. Expense vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ExpreS2ion Biotech Holding AB's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where ExpreS2ion Biotech Holding AB's Selling, General, & Admin. Expense falls into.
ExpreS2ion Biotech Holding AB Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Selling, General, & Admin. Expense of kr0.00 Mil mean?
ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) has a Selling, General, & Admin. Expense of kr0.00 Mil as of Mar. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on ExpreS2ion Biotech Holding AB and its competitors.
Is ExpreS2ion Biotech Holding AB's Selling, General, & Admin. Expense too high?
ExpreS2ion Biotech Holding AB's current Selling, General, & Admin. Expense is kr0.00 Mil. Overall, ExpreS2ion Biotech Holding AB has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ExpreS2ion Biotech Holding AB's Selling, General, & Admin. Expense compare to VRTX and REGN?
ExpreS2ion Biotech Holding AB's Selling, General, & Admin. Expense of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on ExpreS2ion Biotech Holding AB and its competitors. ExpreS2ion Biotech Holding AB's current Selling, General, & Admin. Expense is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ExpreS2ion Biotech Holding AB stock overvalued right now?
Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) is currently considered Possible Value Trap. The stock's GF Value™ is kr3.41, compared to a current price of kr1.45 — trading 57.6% below its estimated fair value. The current Selling, General, & Admin. Expense is kr0.00 Mil. ExpreS2ion Biotech Holding AB's overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For ExpreS2ion Biotech Holding AB (OSTO:EXPRS2), the current Selling, General, & Admin. Expense is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Overvalued in 2026?
Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB stock appears to be undervalued.
The current stock price of kr1.45 is trading 57.6% below its estimated GF Value™ of kr3.41.
GuruFocus considers ExpreS2ion Biotech Holding AB to be Possible Value Trap.
Key valuation signals for OSTO:EXPRS2:
Selling, General, & Admin. Expense: kr0.00 Mil
GF Value™: kr3.41 vs. price of kr1.45 (57.6% below fair value)
No single metric tells the full story. See the OSTO:EXPRS2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ExpreS2ion Biotech Holding AB Business Description
ExpreS2ion Biotech Holding AB is a biotechnology company that develops vaccines. It has developed a human clinical Phase III-validated technology platform, ExpreS2, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Its product pipeline comprises ES2B-C001, a HER2-VLP-based vaccine in development for human breast cancer therapy and several exploratory vaccine projects targeting pathways validated by commercial monoclonal antibody products. Geographically, the company operates in the Nordics region and also has a presence in other countries.
43GF Score
Get the complete analysis for OSTO:EXPRS2
Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:EXPRS2 has been successfully added to your 
